HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Down 11.4% in October

HCW Biologics Inc. (NASDAQ:HCWB) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 24,900 shares, a decrease of 11.4% from the September 30th total of 28,100 shares. Based on an average trading volume of 23,000 shares, the short-interest ratio is presently 1.1 days. Currently, 0.1% of the company’s stock are sold short.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Pullen Investment Management LLC bought a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 85,116 shares of the company’s stock, valued at approximately $149,000. Pullen Investment Management LLC owned 0.23% of HCW Biologics as of its most recent SEC filing. Institutional investors own 2.96% of the company’s stock.

HCW Biologics Stock Down 4.0 %

Shares of HCWB traded down $0.02 on Thursday, reaching $0.43. The company’s stock had a trading volume of 10,539 shares, compared to its average volume of 19,461. The company has a current ratio of 0.10, a quick ratio of 0.10 and a debt-to-equity ratio of 0.95. HCW Biologics has a twelve month low of $0.40 and a twelve month high of $1.93. The stock has a market capitalization of $16.30 million, a PE ratio of -0.41 and a beta of 0.80. The firm has a fifty day moving average of $0.52 and a 200-day moving average of $0.79.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter. The firm had revenue of $0.62 million during the quarter. HCW Biologics had a negative net margin of 978.03% and a negative return on equity of 385.90%.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.